ITGR

Business Context and Reporting Period

Company: Greatbatch, Inc. (Note: Input metadata referenced "Integer Holdings Corp," but the filing text identifies the registrant as Greatbatch, Inc.)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 29, 2007.
Business Overview: Greatbatch operates two segments: Implantable Medical Components (IMC), manufacturing batteries and components for medical devices, and Electrochem Commercial Power (ECP), producing high-performance batteries for commercial applications. The quarter was defined by two strategic acquisitions: BIOMEC, Inc. ($11.4 million) and Enpath Medical, Inc. ($98.2 million).

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Sales increased 11% year-over-year for the quarter ($78.5M vs. $70.6M) and 12% for the six-month period. IMC sales grew 13%, driven by ICD capacitors, feedthroughs, and ICD batteries. ECP sales remained flat.
• Profitability Decline: Net income turned to a loss of $3.4 million for the quarter compared to $4.8 million in the prior year. This was primarily due to $18.4 million in non-cash charges for acquired in-process research and development (IPR&D) from the BIOMEC and Enpath acquisitions.
• Acquisition Impact: The company spent approximately $108 million in cash and short-term investments to acquire BIOMEC and Enpath. This significantly reduced cash reserves from $142.6 million (Dec 2006) to $120.8 million (June 2007) when including short-term investments.
• Debt Restructuring: The company exchanged $117.8 million of existing convertible notes for new notes (CSN II) and issued an additional $80 million in new notes, resulting in a $4.5 million pre-tax gain on extinguishment of debt.

Guidance, Outlook, and Risks

• Management Commentary: Management highlighted record sales for two consecutive quarters and increased operating margins driven by volume and manufacturing initiatives. The acquisitions are viewed as key steps in long-term growth, expanding capabilities in neurostimulation and vascular segments.
• Capital Expenditures: Expected capital spending for 2007 is $35.0 million to $45.0 million, with $20.0 million allocated to a new ECP facility expansion in Massachusetts (completion mid-2008).
• Tax Outlook: The effective tax rate for 2007 is expected to be approximately 47.5%, impacted by the non-deductible portion of the IPR&D charges.
• Risks and Contingencies:
  • Integration Risk: Risks associated with integrating Enpath's operations and realizing projected cost savings.
  • Litigation: Enpath is a defendant in a patent infringement suit regarding its FlowGuard valved introducer. Revenues from this product represented ~5% of Enpath's 2006 revenue. Outcome is uncertain.
  • Customer Concentration: Three customers (Boston Scientific, Medtronic, St. Jude Medical) accounted for 69% of total sales in the first six months of 2007.

Investor Verification Checklist

• Acquisition Valuation: Verify the final purchase price allocation for Enpath and BIOMEC, specifically the valuation of goodwill and IPR&D, as preliminary values are subject to adjustment within 12 months.
• Debt Covenants: Confirm compliance with the new $235 million credit facility covenants, specifically the adjusted EBITDA to interest expense ratio (minimum 3.00:1) and total leverage ratio (maximum 5.00:1).
• IPR&D Commercialization: Monitor the progress of the acquired IPR&D projects (biomimetic coatings and next-gen introducers/catheters) to ensure they reach technological feasibility and FDA approval as projected for 2008-2009.
• Legal Proceedings: Track the status of the patent infringement litigation against Enpath, as an adverse ruling could impact the ability to sell FlowGuard products.
• Inventory Step-Up: Verify the recognition of the remaining $1.1 million inventory step-up value from the Enpath acquisition in the third quarter of 2007.